晚期肝细胞癌系统治疗的研究进展

Research advances in systemic therapy for advanced hepatocellular carcinoma

肝细胞癌(HCC)是一种常见且预后较差的恶性肿瘤,手术切除是治疗HCC的首选方法,但对晚期HCC的治疗效果有限,而系统治疗在晚期不可切除HCC治疗中发挥重要作用。归纳了近年国内外关于不可切除性肝癌系统治疗的相关进展,包括多种酪氨酸激酶抑制剂,如索拉非尼、仑伐替尼、瑞戈非尼和卡博替尼,以及阿替唑珠单抗、帕博利珠单抗、纳武单抗等免疫检查点抑制剂。分析表明,对于不可切除的HCC患者,系统治疗能一定程度上延长患者的生存时间,而联合治疗方案现已成为新的研究热点,未来将进一步探索个体化系统治疗策略。

Hepatocellular carcinoma(HCC)is a common malignant tumor with poor prognosis,and surgical resection is the preferred method for the treatment of HCC,but it has a limited therapeutic effect on advanced HCC,while systemic treatment plays an important role in the treatment of advanced unresectable HCC.This article summarizes the advances in systemic therapy for unresectable liver cancer in China and globally in recent years,including a variety of tyrosine kinase inhibitors(sorafenib,lenvatinib,regorafenib,and cabozantinib)and immune checkpoint inhibitors(atezolizumab,pembrolizumab,and nivolumab).The analysis shows that for patients with unresectable HCC,systemic therapy can prolong the survival time of patients to a certain extent,and combined treatment regimen has become a new research hotspot.Individualized systemic treatment strategies will be further explored in the future.